Sandoz U.S. President Peter Goldschmidt: An Interview With “The Pink Sheet” DAILY
This article was originally published in The Pink Sheet Daily
In an interview at Novartis’ U.S. headquarters, Goldschmidt talked about the Novartis unit’s approach to launching the first biosimilar in the U.S., and the other future growth drivers for Sandoz, including complex generics like Glatopa.
You may also be interested in...
Interactive chart of growing 351(k) pipeline shows that while Phase III is dominated by big players, pure-play biosimilar companies are beginning to emerge.
FDA’s approval of the first ANDA for an MS therapy signals the agency’s determination to find a way to get generic versions of complex drugs to market. What if any lessons does that hold for biosimilars?
A Phase III trial testing dapagliflozin in chronic kidney disease patients with and without diabetes was stopped early following a recommendation from an independent data monitoring committee.